MA54861A - Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile - Google Patents

Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile

Info

Publication number
MA54861A
MA54861A MA054861A MA54861A MA54861A MA 54861 A MA54861 A MA 54861A MA 054861 A MA054861 A MA 054861A MA 54861 A MA54861 A MA 54861A MA 54861 A MA54861 A MA 54861A
Authority
MA
Morocco
Prior art keywords
receptor antibodies
idiopathic arthritis
juvenile idiopathic
treating juvenile
treating
Prior art date
Application number
MA054861A
Other languages
English (en)
Inventor
Lydie Baret-Cormel
Stefano Fiore
Tanya Momtahen
Adelsberg Janet Van
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of MA54861A publication Critical patent/MA54861A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA054861A 2019-01-31 2020-01-31 Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile MA54861A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962799698P 2019-01-31 2019-01-31
US201962851474P 2019-05-22 2019-05-22
US201962935395P 2019-11-14 2019-11-14
EP19306553 2019-12-03

Publications (1)

Publication Number Publication Date
MA54861A true MA54861A (fr) 2021-12-08

Family

ID=69646033

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054861A MA54861A (fr) 2019-01-31 2020-01-31 Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile

Country Status (14)

Country Link
US (2) US11498969B2 (fr)
EP (1) EP3917618A1 (fr)
JP (1) JP7542543B2 (fr)
KR (1) KR20210122810A (fr)
CN (1) CN114206442A (fr)
AU (1) AU2020216978A1 (fr)
BR (1) BR112021014377A2 (fr)
CA (1) CA3128212A1 (fr)
CO (1) CO2021011352A2 (fr)
IL (1) IL284890A (fr)
MA (1) MA54861A (fr)
MX (1) MX2021009242A (fr)
SG (1) SG11202107735SA (fr)
WO (1) WO2020160465A1 (fr)

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
ES2093017T3 (es) 1989-07-20 1996-12-16 Tadamitsu Kishimoto Anticuerpo contra el receptor de la interleuquina-6 humana.
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
DE10199067I2 (de) 1991-03-18 2006-03-16 Univ New York Fuer Menschlichen Tumornekrose-Faktor spezifische Monoklonale und Chimaere Antikoerper
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
JPH09505721A (ja) 1992-10-20 1997-06-10 シータス オンコロジー コーポレイション インターロイキン６レセプターアンタゴニスト
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
EP0783893B1 (fr) 1994-10-07 2012-04-04 Chugai Seiyaku Kabushiki Kaisha Inhibition de la croissance anormale de cellules synoviales a l' aide d' un antagoniste d'interleukine 6 comme principe actif
CZ298325B6 (cs) 1994-10-21 2007-08-29 Kishimoto@Tadamitsu Farmaceutický prípravek pro prevenci nebo lécení plasmocytosy
AU704723B2 (en) 1994-12-29 1999-04-29 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
DE69636278T2 (de) 1995-02-13 2007-05-03 Chugai Seiyaku K.K. Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
PL187733B1 (pl) 1996-02-26 2004-09-30 Advanced Res & Tech Inst Zastosowanie inhibitora anhydrazy węglanowej
DE69735888T2 (de) 1996-06-27 2006-11-02 Chugai Seiyaku K.K. Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoffsenfgasen verwendet werden kann
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
CA2296322A1 (fr) 1997-08-15 1999-02-25 Chugai Seiyaku Kabushiki Kaisha Preventifs et/ou medicaments contre le lupus erythemateux systemique, contenant un anticorps anti-recepteur d'il-6 comme ingredient actif
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
CZ297083B6 (cs) 1998-03-17 2006-09-13 Chugai Seiyaku Kabushiki Kaisha Cinidlo pro prevenci a lécbu zánetlivého onemocnení streva obsahující aktivní slozku antagonistu IL-6
ATE350060T1 (de) 1998-08-24 2007-01-15 Chugai Pharmaceutical Co Ltd Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
ATE316531T1 (de) 1999-10-07 2006-02-15 Lilly Co Eli Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
EP1314437B1 (fr) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
EP1327681A4 (fr) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Anticorps agoniste degrade
DE60133029T2 (de) 2000-10-25 2009-03-12 Chugai Seiyaku K.K. Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
AU2000279625A1 (en) 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
CA2385745C (fr) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
WO2003009817A2 (fr) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Formulation pharmaceutique lyophilisee stable d'anticorps igg
ES2624547T3 (es) 2001-11-14 2017-07-14 Janssen Biotech, Inc. Anticuerpos anti il 6, composiciones, métodos y usos
JP3792698B2 (ja) 2002-02-14 2006-07-05 中外製薬株式会社 抗体含有溶液製剤
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078533A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060078531A1 (en) 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
BRPI0403964B8 (pt) 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
CN1802176A (zh) 2003-04-09 2006-07-12 健泰科生物技术公司 治疗对tnf－alpha抑制剂应答不充分的患者中的自身免疫病
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005028514A1 (fr) 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg. Utilisation d'un compose pour reduire l'efficacite biologique de l'il-6
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
US20080145367A1 (en) 2004-02-11 2008-06-19 Warner-Lambert Compay, Llc Methods of Treating Osteoarthritis with Il-6 Antagonists
US8895521B2 (en) 2004-05-06 2014-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
RS20070027A (en) 2004-07-26 2008-11-28 Biogen Idec Ma Inc., Anti-cd154 antibodies
US20070036788A1 (en) 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
EP1810980A1 (fr) 2004-10-28 2007-07-25 Osaka University Agents inhibiteur de l interleucine-6
KR20070095949A (ko) 2004-12-16 2007-10-01 제넨테크, 인크. 자가면역 장애의 치료 방법
EP1951305A1 (fr) 2005-11-22 2008-08-06 Wyeth a Corporation of the State of Delaware Preparations a base de proteines hybrides d'immunoglobuline
ES2672221T3 (es) 2005-12-13 2018-06-13 Eli Lilly And Company Anticuerpos anti IL-17
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
CN102585002A (zh) 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
KR20090021298A (ko) 2006-06-14 2009-03-02 임클론 시스템즈 인코포레이티드 항-ｅｇｆｒ 항체의 동결건조 제제
WO2008020079A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Séquences d'acides aminés dirigées contre l'il-6r et polypeptides les contenant utilisés pour le traitement de maladies et de troubles associés au signal médié par il-6
WO2008049897A1 (fr) 2006-10-27 2008-05-02 Ablynx N.V. Administration intranasale de polypeptides et de protéines
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
TWI578998B (zh) 2007-09-26 2017-04-21 中外製藥股份有限公司 抗ｉｌ－６受體的抗體
WO2009095489A2 (fr) 2008-02-01 2009-08-06 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
WO2009109584A1 (fr) 2008-03-07 2009-09-11 Ferring International Center S. A. Anticorps qui ne se lie qu'au complexe il6-sil6r
PT2275443E (pt) 2008-04-11 2016-03-15 Chugai Pharmaceutical Co Ltd Moléculas de ligação ao antigénio capazes de se ligarem, repetidamente, a duas ou mais moléculas de antigénio
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
SG10201900451SA (en) 2009-03-19 2019-02-27 Chugai Pharmaceutical Co Ltd Pharmaceutical formulation containing improved antibody molecules
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
KR20130065662A (ko) 2010-05-07 2013-06-19 조마 테크놀로지 리미티드 ⅠＬ-1β 관련 병태의 치료 방법
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
EP2638067A2 (fr) * 2010-11-08 2013-09-18 Genentech, Inc. Anticorps anti-récepteur de l'il-6 administré par voie sous-cutanée
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
KR20220056254A (ko) * 2013-11-22 2022-05-04 사노피 바이오테크놀로지 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
BR112016027893A2 (pt) * 2014-05-29 2017-10-24 Macrogenics Inc molécula de ligação triespecífica, e, composição farmacêutica
ES2894259T3 (es) 2014-09-16 2022-02-14 Sanofi Biotechnology Composiciones para mejorar la calidad de vida relacionada con la salud de pacientes con artritis reumatoide
AU2016348418B8 (en) 2015-11-03 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
SG11201807614SA (en) * 2016-03-07 2018-10-30 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
PE20211196A1 (es) * 2018-01-05 2021-07-01 Novo Nordisk As Metodos para tratar inflamacion mediada por il-6 sin inmunosupresion

Also Published As

Publication number Publication date
TW202043285A (zh) 2020-12-01
US20230127528A1 (en) 2023-04-27
CN114206442A (zh) 2022-03-18
WO2020160465A1 (fr) 2020-08-06
WO2020160465A9 (fr) 2020-10-15
CA3128212A1 (fr) 2020-08-06
US20200339693A1 (en) 2020-10-29
IL284890A (en) 2021-08-31
JP7542543B2 (ja) 2024-08-30
CO2021011352A2 (es) 2021-12-10
JP2022519828A (ja) 2022-03-25
US11498969B2 (en) 2022-11-15
BR112021014377A2 (pt) 2021-12-28
AU2020216978A1 (en) 2021-09-09
EP3917618A1 (fr) 2021-12-08
MX2021009242A (es) 2021-10-26
KR20210122810A (ko) 2021-10-12
SG11202107735SA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
MA53330A (fr) Constructions d'anticorps pour cldn18.2 et cd3
MA51993A (fr) Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur
MA49911A (fr) Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
MA51042A (fr) Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA44594B1 (fr) Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
MX362591B (es) Uso de antagonistas de il-17.
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA51903A (fr) Formulations d'anticorps b7-h4
MA54052A (fr) Formulation d'anticorps
MA52545A (fr) Anticorps pour radionucléides chélatés
MY167233A (en) Il-17 antibody formulation
EA201892005A1 (ru) Композиции и способы для лечения ревматоидного артрита
MA55033A (fr) Formulation d'anticorps thérapeutique
MA55284A (fr) Procédés de production de compositions d'anticorps anti-tnf
MA51902A (fr) Schémas posologiques d'anticorps b7-h4
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
MA55282A (fr) Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
MA54861A (fr) Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
MA55283A (fr) Procédés de production de compositions d'anticorps anti-tnf
MA51750A (fr) Appareil d'égalisation d'usure pour cyclones
MA54464A (fr) Anticorps humanisé anti-récepteur de l'igf-i
MA55967A (fr) Procédés d'administration d'anticorps anti-cd38 pour traiter le myélome multiple
MA47106A (fr) Formulations d'anticorps anti-tnf alpha
MA51992A (fr) Anticorps anti-cd25 pour la déplétion de cellules spécifiques d'une tumeur